Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma. Issue 6 (2nd November 2021)

• Record Type: Journal Article
• Authors: Savarapu, Pramod; Abdelazeem, Basel; Isa, Sakiru; Kesari, Kavitha; Kunadi, Arvind
• Is Part Of: Journal of community hospital internal medicine perspectives. Volume 11:Issue 6(2021)
• Page Start: 874
• Page End: 876
• Publication Date: 2021-11-02
• Subjects: Ipilimumab -- nivolumab -- checkpoint inhibitor -- immune-related adverse events ventricular tachycardia -- cardiotoxicity -- cardiomyopathy -- case report; Internal medicine -- Periodicals; Hospitals -- Periodicals; Hospitals, Community; Internal Medicine; Hospitals; Internal medicine; Periodicals; Periodicals; 610
• DOI: 10.1080/20009666.2021.1965708
• Languages: English
• ISSNs: 2000-9666

Abstract

ABSTRACT: The immune checkpoint inhibitor (ICIs) as Nivolumab and Ipilimumab is a novel class of medication used in the management of several metastatic malignancies. ICIs can cause immune-related adverse events due to autoreactive T cell activation. Cardiovascular complications comprised myocarditis, conduction abnormalities, ventricular storm, and cardiomyopathy. Cardiomyopathy is one of the significant side effects highlighted in some of the case reports. The physicians should include autoimmune toxicities as the potential differential diagnosis in patients presenting with an unusual presentation and receiving ICIs. We report a case of a 66-year-old female with advanced renal cell carcinoma who developed cardiomyopathy and ventricular tachycardia from nivolumab and ipilimumab therapy.